




# YOUR GUIDE TO GIVING A SUBCUTANEEOUS INJECTION




**STEP 1**  
Allow the medication to come to room temperature. Once it does, use an alcohol swab to clean the injection site. Let it dry for 10 seconds. Do not blow on it.




**STEP 2**  
Gently pinch the skin, avoiding any muscles. Insert the needle into the skin at a 45° or 90° angle with a quick, firm action. Follow your provider’s instructions.




**STEP 3**  
After you insert the needle completely, release your pinch of the skin.



**STEP 4**  
Slowly inject the solution by gently pushing the plunger all the way down.



**STEP 5**  
Withdraw the needle at the same angle as inserted. Do not rub the injection site. If there is bruising, an ice pack can also be applied with gentle pressure.



## WHERE TO INJECT

You can inject in a few different areas: the outer arm, the stomach, and the outer thigh. The stomach is often the easiest.

**Rotate between the different sites for each injection.**

# YOUR HEMLIBRA DOSING PLAN

Use this form to stay on schedule with your HEMLIBRA loading and maintenance doses.

## STARTING HEMLIBRA

Inject HEMLIBRA (3 mg/kg) under the skin (subcutaneously) once a week for the first 4 weeks of treatment. HEMLIBRA is dosed by weight.

- Stop taking prophylactic bypassing therapy the day before starting HEMLIBRA
- You may continue to use prophylactic factor VIII for the first week of HEMLIBRA after your loading dose. Talk with your healthcare provider (HCP) for specific guidance

LOADING DOSE (WEEKS 1-4)

LOADING DOSE DATE	MILLIGRAMS
1.	
2.	
3.	
4.	

MAINTENANCE DOSE (WEEKS 5+)

YOUR FIRST MAINTENANCE DOSE IS ON \_\_\_\_\_

AND SHOULD BE TAKEN EVERY \_\_\_\_\_ WEEK(S).

YOUR MAINTENANCE DOSE IS \_\_\_\_\_ MILLIGRAMS.

- If your weight changes, tell your HCP
- If you miss a dose on your scheduled day, you should take the dose as soon as you remember, then continue with your normal dosing schedule
- Do not take 2 doses on the same day to make up for a missed dose. Be sure to consult your HCP with any questions

## What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

Please [click here](#) to see Important Safety Information, including **Serious Side Effects**, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

## YOU MAY NEED TO TREAT A BLEED WHILE ON HEMLIBRA

HEMLIBRA is for routine prophylaxis only. Do not use HEMLIBRA to treat a breakthrough bleed.

- You should continue to stay on your HEMLIBRA prophylaxis regimen while treating breakthrough bleeds

YOUR BREAKTHROUGH BLEED PLAN

## What is the most important information I should know about HEMLIBRA?


**HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.**



## HEMLIBRA RESOURCES FOR YOU

---

Check out some of the extra resources below to help guide you through your experience with HEMLIBRA.



Refer to the [Learning How to Inject Brochure](#) or [Learning How to Inject Video](#) for step-by-step instructions on administering HEMLIBRA.



[Contact an Account and Community Manager \(ACM\)](#) for someone to talk to if you have any questions or if you did not receive a Welcome Kit. ACMs are Genentech employees and experts on HEMLIBRA; however, they do not provide medical advice. If you have any questions about your medical condition, contact your doctor.



Being ready for an emergency situation is important. Consider updating your emergency medical information and carrying an [Emergency Room \(ER\) Card](#) so ER staff know you are taking HEMLIBRA.

Please [click here](#) to see Important Safety Information, including **Serious Side Effects**, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

# IMPORTANT SAFETY INFORMATION

## What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

## What is the most important information I should know about HEMLIBRA?

**HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.**

**These serious side effects include:**

- **Thrombotic microangiopathy (TMA)**, a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- **Blood clots (thrombotic events)**, which may form in blood vessels in your arm, leg, lung, or head

**Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.**

**Your body may make antibodies against HEMLIBRA, which may stop HEMLIBRA from working properly. Contact your healthcare provider immediately if you notice that HEMLIBRA has stopped working for you (eg, increase in bleeds).**

**The most common side effects of HEMLIBRA include:** injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

## What else should I know about HEMLIBRA?

**See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.**

- **Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA**
- **You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA**

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

Side effects may be reported to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including **Serious Side Effects**, as well as the HEMLIBRA full [Prescribing Information](#) and [Medication Guide](#).

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.  
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.  
The Genentech logo is a registered trademark of Genentech, Inc.  
All other trademarks are the property of their respective owners.  
© 2023 Genentech USA, Inc. All rights reserved. For U.S. residents only. M-US-00007691(v3.0) 08/23

**Genentech**  
*A Member of the Roche Group*

  
**HEMLIBRA®**  
emicizumab-kxwh | 150 mg/mL  
injection for subcutaneous use